KW 040
Alternative Names: KW-040Latest Information Update: 15 Oct 2023
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 06 Sep 2023 Preclinical trials in Hepatitis B in China (Parenteral), prior to September 2023 (Beijing kawin technology share holding pipeline, September 2023)